journal
https://read.qxmd.com/read/38460077/should-glucokinase-be-given-a-chance-in-diabetes-therapeutics-a-clinical-pharmacological-review-of-dorzagliatin-and-lessons-learned-so-far
#1
REVIEW
Upinder Kaur, Bhairav Kumar Pathak, Tharik Jalal Meerashahib, Dondapati Venkata Vamshi Krishna, Sankha Shubhra Chakrabarti
Despite advances in the management of type 2 diabetes mellitus (T2DM), one-third of patients with diabetes do not achieve the desired glycemic goal. Considering this inadequacy, many agents that activate glucokinase have been investigated over the last two decades but were withdrawn before submission for marketing permission. Dorzagliatin is the first glucokinase activator that has been granted approval for T2DM, only in China. As overstimulation of glucokinase is linked with pathophysiological disturbances such as fatty liver and cardiovascular issues and a loss of therapeutic efficacy with time...
March 9, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38446396/effectiveness-of-dose-increase-in-upadacitinib-from-15-mg-to-30-mg-for-patients-with-moderate-to-severe-atopic-dermatitis-a-real-world-clinical-practice-in-japan
#2
JOURNAL ARTICLE
Teppei Hagino, Risa Hamada, Mai Yoshida, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
BACKGROUND: Atopic dermatitis is characterized by persistent eczema and pruritus. Janus kinase inhibitors, including upadacitinib, are effective treatments for moderate-to-severe atopic dermatitis. If patients do not respond well to a certain dose of a Janus kinase inhibitor, increasing the dose may improve their treatment responsiveness. OBJECTIVES: We assessed the outcomes of a dose increase in upadacitinib from 15 mg to 30 mg for Japanese patients with moderate-to-severe atopic dermatitis...
March 6, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38430434/tolvaptan-treatment-and-long-term-impact-on-quality-of-life-in-autosomal-dominant-polycystic-kidney-disease-patients-a-pilot-study
#3
LETTER
Gianni Carraro, Valentina Di Vico, Loris Martinetti, Elisabetta Bettin, Martina Cacciapuoti, Lucia Federica Stefanelli, Laura Gobbi, Federico Nalesso, Francesca Katiana Martino, Lorenzo A Calò
No abstract text is available yet for this article.
March 2, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38388986/an-open-label-study-to-assess-monthly-risperidone-injections-180-mg-following-switch-from-daily-oral-risperidone-6-mg-in-stable-schizophrenic-patients
#4
JOURNAL ARTICLE
David P Walling, Sunita N Shinde, Janice M Pogoda, Jahnavi Kharidia, Celine M Laffont
BACKGROUND AND OBJECTIVE: Long-acting injectable antipsychotics have shown benefits over oral medications with reduced hospitalization rates and improved health-related quality of life. RBP-7000 (PERSERIS® ) is a monthly risperidone formulation (90 or 120 mg) for the treatment of schizophrenia administered by subcutaneous abdominal injection. The objective of this study was to assess a higher dose of 180 mg RBP-7000 and an alternate injection site. METHODS: Following stabilization on 6 mg/day (3 mg twice daily) oral risperidone, clinically stable schizophrenic participants received 3 monthly doses of 180 mg RBP-7000 in the abdomen followed by a fourth monthly dose of 180 mg RBP-7000 in the upper arm (each dose administered as two 90-mg injections)...
February 22, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38381352/cost-effectiveness-evaluation-of-oral-cgrp-antagonists-atogepant-and-rimegepant-for-the-preventative-treatment-of-episodic-migraine-results-from-a-us-societal-perspective-model
#5
JOURNAL ARTICLE
Ryan Thaliffdeen, Anthony Yu, Karen Rascati
BACKGROUND AND OBJECTIVES: Two oral calcitonin gene-related peptide (CGRP) antagonists, atogepant and rimegepant, were approved in 2021 for the preventive treatment of episodic migraine (EM), yet no formal cost-effectiveness analysis has been published. The objective of this study was to evaluate the cost-effectiveness of atogepant 60 mg and rimegepant 75 mg compared with placebo. METHODS: A decision tree model was constructed over a 1-year time horizon from a US societal perspective...
February 21, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38379107/real-world-effectiveness-of-sotrovimab-for-the-early-treatment-of-covid-19-evidence-from-the-us-national-covid-cohort-collaborative-n3c
#6
JOURNAL ARTICLE
Christopher F Bell, Priyanka Bobbili, Raj Desai, Daniel C Gibbons, Myriam Drysdale, Maral DerSarkissian, Vishal Patel, Helen J Birch, Emily J Lloyd, Adina Zhang, Mei Sheng Duh
BACKGROUND AND OBJECTIVE: The coronavirus disease 2019 (COVID-19) pandemic has been an unprecedented healthcare crisis, one that threatened to overwhelm health systems and prompted an urgent need for early treatment options for patients with mild-to-moderate COVID-19 at high risk for progression to severe disease. Randomised clinical trials established the safety and efficacy of monoclonal antibodies (mAbs) early in the pandemic; in vitro data subsequently led to use of the mAbs being discontinued, without clear evidence on how these data were linked to outcomes...
February 20, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38376794/thromboembolic-events-associated-with-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-a-pharmacovigilance-analysis-of-the-us-fda-adverse-event-reporting-system-faers-database
#7
JOURNAL ARTICLE
Xiongwen Yang, Bo Yang, Dan Li, Wei Pan, Qin Tong, Lili Wang, Danjun Chen, Chengxiao Fu
BACKGROUND AND OBJECTIVES: Although thromboembolic events (TEEs) have been reported with the use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), their association remains largely unknown. In this study, we aimed to provide a comprehensive review of TEEs associated with EGFR-TKIs. METHODS: We collected EGFR-TKIs (gefitinib, erlotinib, afatinib, and osimertinib) adverse reaction reports from 2015 Q1 to 2023 Q1 from the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database...
February 20, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38372935/safety-and-efficacy-of-biologic-medications-and-janus-kinase-inhibitors-in-patients-with-down-syndrome-a-retrospective-cohort-study
#8
LETTER
Linnea Westerkam, Lauren Pearson, Christopher Sayed
No abstract text is available yet for this article.
February 19, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38363545/safety-of-intravenous-push-valproate-compared-with-intravenous-piggyback-at-a-tertiary-academic-medical-center
#9
JOURNAL ARTICLE
Felicia Y Wang, Kevin C McLaughlin, Michael J Schontz, Jeremy R DeGrado, Robert E Dannemiller
BACKGROUND AND OBJECTIVES: Data are limited regarding the safety associated with administering valproate sodium by intravenous push (IVP) compared with intravenous piggyback (IVPB). The objective of this retrospective pre-post analysis was to compare the safety profile of valproate administration via IVPB from March to May 2022 and IVP from June to August 2022. METHODS: A total of 890 IVPB and 440 IVP administrations were included. The major endpoint of this analysis was the incidence of infusion site reactions (infiltration or phlebitis)...
February 16, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38326641/effect-of-ticagrelor-versus-clopidogrel-on-all-cause-and-cardiovascular-mortality-in-acute-coronary-syndrome-patients-with-hyperuricemia
#10
JOURNAL ARTICLE
Shanshan Nie, Yuhang Zhao, Zeying Feng, Chan Zou, Fangfang Ding, Liying Gong, Hongwei Lu, Yu Cao, Guoping Yang
BACKGROUND AND OBJECTIVE: The relationship between hyperuricemia and mortality in patients with acute coronary syndrome (ACS) is considerably controversial. Additionally, the strategy of dual antiplatelet therapy (DAPT) has not been evaluated in patients with ACS with hyperuricemia. This study aims to evaluate the impact of hyperuricemia on the prognosis of ACS and explore the efficacy of ticagrelor compared with clopidogrel in patients with hyperuricemia. METHODS: The study enrolled 4319 patients divided into hyperuricemia (HUA, n = 1060) and normouricemia (NUA, n = 3259) groups...
February 7, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38294672/forty-eight-month-monitoring-of-disease-activity-in-patients-with-long-standing-rheumatoid-arthritis-treated-with-tnf-%C3%AE-inhibitors-time-for-clinical-outcome-prediction-and-biosimilar-vs-biologic-originator-performance
#11
JOURNAL ARTICLE
Matteo Colina, Micheline Khodeir, Roberto Rimondini, Marco Valentini, Federica Campomori, Stefania Corvaglia, Gabriele Campana
BACKGROUND AND OBJECTIVES: Long-term treatment of patients with rheumatoid arthritis with tumor necrosis factor-α inhibitors leads to initial changes in disease activity that can predict a late treatment response. This observational and retrospective study aimed to determine when it is possible to foresee the response to therapy in the case of long-standing rheumatoid arthritis comparing also the efficacy of the original biologics with their biosimilars. METHODS: A total of 1598 patients were recruited and treated with the original biologics, adalimumab and etanercept, or with biosimilars...
January 31, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38198117/correction-to-association-between-antidiabetic-drugs-and-delirium-a-study-based-on-the-adverse-drug-event-reporting-database-in-japan
#12
Yukiko Ishibashi, Rintaro Sogawa, Kenji Ogata, Ayaka Matsuoka, Haruna Yamada, Toru Murakawa-Hirachi, Yoshito Mizoguchi, Akira Monji, Chisato Shimanoe
No abstract text is available yet for this article.
January 10, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38198116/demystifying-dry-powder-inhaler-resistance-with-relevance-to-optimal-patient-care
#13
REVIEW
Toby G D Capstick, Sanjay Gudimetla, David S Harris, Rachel Malone, Omar S Usmani
The selection of an inhaler device is a key component of respiratory disease management. However, there is a lack of clarity surrounding inhaler resistance and how it impacts inhaler selection. The most common inhaler types are dry powder inhalers (DPIs) that have internal resistance and pressurised metered dose inhalers (pMDIs) that use propellants to deliver the drug dose to the airways. Inhaler resistance varies across the DPIs available on the market, depending largely on the design geometry of the device but also partially on formulation parameters...
January 10, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38195833/a-real-world-observational-study-to-evaluate-the-safety-and-effectiveness-of-fluticasone-furoate-oxymetazoline-fixed-dose-combination-nasal-spray-in-patients-with-allergic-rhinitis
#14
JOURNAL ARTICLE
Meenesh R Juvekar, Gauri Kapre Vaidya, Aniruddha Majumder, Amod D Pendharkar, Anthony Irudhayarajan, Avijit Kundu, D Ramesh, J Dheeraj Kumar, B Jagannatha, Joseph Mathew, Mahesh P Nikam, Madhuri Mehta, Neeraj Chawla, Priti Hajare, P G Chandre Gowda, P V L N Murthy, Suma Moni Mathew, Makarand V Damle, Chandra Kant, Arun B Nair, Ashok Jaiswal, Ravi T Mehta
BACKGROUND: Allergic rhinitis (AR) has shown an increasing prevalence leading to a considerable medical and social burden. Nasal congestion is the cardinal symptom of AR, and the upper respiratory tract is most affected by this long-lasting ailment. Intranasal corticosteroids alleviate nasal congestion, along with other symptoms of AR, but their effect is not evident immediately. Oxymetazoline has a rapid onset of action, but its use should be limited to 3-5 days. OBJECTIVE: The study aimed to evaluate the safety and effectiveness of the fixed-dose combination nasal spray containing fluticasone furoate and oxymetazoline hydrochloride (FF + OXY) 27...
January 9, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38170348/antibiotic-associated-acute-kidney-injury-among-older-adults-a-case-crossover-study
#15
JOURNAL ARTICLE
Tichawona Chinzowu, Te-Yuan Chyou, Prasad S Nishtala
BACKGROUND AND OBJECTIVES: Drug-related acute kidney injury is quite common in older adults. The associated drugs, including antibiotics, are often co-prescribed. The objective of this study was to ascertain antibiotic-associated acute kidney injury (AKI) in older adults aged 65 years or above in New Zealand using a case-crossover study design. METHODS: The International Statistical Classification of Diseases and Related Health Problems, tenth revision, Australian modification code N17...
January 3, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38135802/association-between-antidiabetic-drugs-and-delirium-a-study-based-on-the-adverse-drug-event-reporting-database-in-japan
#16
JOURNAL ARTICLE
Yukiko Ishibashi, Rintaro Sogawa, Kenji Ogata, Ayaka Matsuoka, Haruna Yamada, Toru Murakawa-Hirachi, Yoshito Mizoguchi, Akira Monji, Chisato Shimanoe
BACKGROUND AND OBJECTIVE: Several associations between diabetes mellitus and delirium have been reported; however, they have been inconsistent, and evidence on the effects of antidiabetic medications on delirium is also limited. This study aimed to investigate whether the use of antidiabetic drugs is a risk factor for delirium development. METHODS: Using the Japanese Adverse Event Reporting Database, we analyzed 662,899 reports between 2004 and 2022. Reporting odds ratios (RORs) and 95% confidence intervals (CIs) for delirium associated with diabetes and using each antidiabetic medication were calculated after adjusting for potential confounders...
December 23, 2023: Clinical Drug Investigation
https://read.qxmd.com/read/38300386/cost-effectiveness-analysis-of-camrelizumab-plus-rivoceranib-versus-sorafenib-as-a-first-line-therapy-for-unresectable-hepatocellular-carcinoma-in-the-chinese-health-care-system
#17
RANDOMIZED CONTROLLED TRIAL
Wenwang Lang, Lian Deng, Bei Huang, Dongmei Zhong, Gaofeng Zhang, Meijun Lu, Ming Ouyang
BACKGROUND AND OBJECTIVES: Camrelizumab plus rivoceranib showed significant clinical benefits in progression-free survival and overall survival compared to sorafenib in patients with unresectable hepatocellular carcinoma (HCC). This study aimed to assess its cost effectiveness from the perspective of Chinese health care system. METHODS: A Markov state-transition model was developed based on the Phase 3 randomized CARES-310 clinical trial data. Health state utility values were obtained from the CARES-310 clinical trial, and direct medical costs were derived from the relevant literature and local charges...
March 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38182963/maximizing-the-value-of-chronic-myeloid-leukemia-management-using-tyrosine-kinase-inhibitors-in-the-usa-potential-determinants-and-consequences-of-healthcare-resource-utilization-and-costs-with-proposed-optimization-approaches
#18
Jeffrey H Lipton
BACKGROUND AND OBJECTIVES: The introduction and widespread use of effective and well-tolerated tyrosine kinase inhibitors for chronic myeloid leukemia have been associated with marked increments in life expectancy and disease prevalence. These changes have been accompanied by elevations in costs of tyrosine kinase inhibitors, which typically must be taken ad vitam after diagnosis and tend to be more expensive than medical therapies for many other hematologic malignancies. The aims of this review included evaluating the potential associations and consequences of healthcare resource utilization and costs of tyrosine kinase inhibitors and possible clinical management approaches to mitigate them...
February 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38036930/key-drivers-of-coagulation-factor-use-in-von-willebrand-disease-during-hospitalization-an-overview-of-the-french-berhlingo-cohort
#19
JOURNAL ARTICLE
Valérie Horvais, Philippe Beurrier, Vincent Cussac, Brigitte Pan-Petesch, Solène Schirr-Bonnans, Johann Rose, Sophie Bayart, Catherine Ternisien, Marc Fouassier, Marianne Sigaud, Antoine Babuty, Nicolas Drillaud, Benoît Guillet, Marc Trossaërt
BACKGROUND: Von Willebrand disease (VWD) is the most common inherited bleeding disorder. However, studies of hospitalisation patterns with replacement treatment are scarce. OBJECTIVES: The aim of this study was to investigate the current therapeutic management of VWD and determine the key drivers of coagulation factor uses in patients during hospitalisation. METHODS: Hopscotch-WILL was a multi-centric retrospective study conducted over a 48-month period in any patients with VWD...
January 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38114780/real-world-effectiveness-and-safety-of-baricitinib-in-patients-with-atopic-dermatitis
#20
LETTER
Egídio Freitas, Maria João Paiva Lopes, Maria João Cruz, Diogo Sousa, Ana Clara Valente, Bruno Duarte, Laetitia Teixeira, Gilberto Rosas, Mónica Caetano, Alberto Mota, Paulo Filipe, Tiago Torres
No abstract text is available yet for this article.
December 19, 2023: Clinical Drug Investigation
journal
journal
32205
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.